Race Oncology (ASX:RAC) said no vein inflammation or any other adverse events were reported after its first patient was administered a dose of its drug candidate, reformulated bisantrene (RC220), in the phase one clinical trial for advanced solid tumor patients, according to a Tuesday filing with the Australian bourse.
The trial aims to assess the safety, tolerability, and pharmacokinetics of RC220 in combination with the chemotherapy drug doxorubicin, the filing said.
Stage one will enroll up to 33 patients across multiple sites in Australia, Hong Kong, and South Korea, the filing added.
After an interim analysis, the optimal dosage of RC220 combined with doxorubicin will be evaluated in an additional 20 patients in stage two of the trial, the filing added.
Shares of the company jumped 14% in recent Thursday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。